Endologix
Financials
Estimates*
USD | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
---|---|---|---|---|---|---|---|
Revenues | - | 181m | 157m | 143m | 113m | 144m | 152m |
% growth | - | - | (13 %) | (9 %) | (21 %) | 27 % | 6 % |
EBITDA | - | (19.0m) | (43.0m) | (24.0m) | (42.0m) | (22.0m) | - |
% EBITDA margin | - | (10 %) | (27 %) | (17 %) | (37 %) | (15 %) | - |
Profit | - | (66.0m) | (79.0m) | (64.0m) | (94.0m) | (69.0m) | - |
% profit margin | - | (36 %) | (50 %) | (45 %) | (83 %) | (48 %) | - |
R&D budget | 34.1m | - | - | - | - | - | - |
Source: Dealroom estimates
Date | Investors | Amount | Round |
---|---|---|---|
N/A | N/A | IPO | |
N/A | $9.0m | Post IPO Equity | |
N/A | $16.6m | Post IPO Equity | |
$15.0m | Post IPO Equity | ||
$170m | Post IPO Debt | ||
Total Funding | - |
Recent News about Endologix
EditEndologix is a medical device company specializing in innovative vascular therapies aimed at improving patient outcomes. The company focuses on developing groundbreaking solutions for the treatment of abdominal aortic aneurysms (AAA) and peripheral artery disease (PAD). Endologix serves healthcare professionals and patients by providing advanced medical devices that offer durable and personalized repair options. The company's flagship products include the AFX, Ovation, and ALTO systems, which are designed to preserve native bifurcation and ensure reliable, stable repairs. Endologix operates in the medical devices market and generates revenue through the sale of its specialized vascular therapy products. The business model revolves around continuous innovation and clinical excellence to meet the critical unmet needs in vascular care.
Keywords: vascular therapies, medical devices, AAA treatment, PAD solutions, healthcare professionals, patient outcomes, durable repair, personalized care, clinical excellence, innovation.